SCHEMBL31225855

SCHEMBL31225855

O=C(Cc1ccc(C(F)F)cc1)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
SENP1 Q9P0U3 2/20 0.42
KMT2A Q03164 6/20 0.40
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
ATM Q13315 1/20 0.39
HTT P42858 1/20 0.39
TSHR P16473 1/20 0.37
CYP4F2 P78329 1/20 0.37
CYP4A11 Q02928 1/20 0.37
UCHL1 P09936 1/20 0.36
USP5 P45974 1/20 0.36
USP4 Q13107 1/20 0.36
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226055 0.83 KMT2A (0.55) SMN1; SMN2SENP1KMT2AALDH1A1HPGD
SCHEMBL9059841 0.81 SMN1; SMN2 (0.47) SMN1; SMN2SENP1KMT2AALDH1A1HPGD
SCHEMBL31226071 0.81 SENP1 (0.61) SMN1; SMN2SENP1KMT2AALDH1A1HPGD
SCHEMBL31225821 0.80 KMT2A (0.52) SMN1; SMN2SENP1KMT2AALDH1A1L3MBTL1
SCHEMBL6937307 0.80 SMN1; SMN2 (0.67) SMN1; SMN2SENP1KMT2AALDH1A1HPGD
SCHEMBL17966287 0.80 CYP4F2 (0.58) SMN1; SMN2KMT2AALDH1A1L3MBTL1HTT
SCHEMBL31225539 0.79 KMT2A (0.51) SMN1; SMN2SENP1KMT2AALDH1A1HPGD
SCHEMBL5715921 0.77 SMN1; SMN2 (0.50) SMN1; SMN2SENP1KMT2AL3MBTL1MAPT
SCHEMBL31225490 0.77 SMN1; SMN2 (0.55) SMN1; SMN2SENP1KMT2AALDH1A1HTT
SCHEMBL14744261 0.75 PSIP1 (0.45) SMN1; SMN2SENP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727537-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF Adaxion Therapeutics, Inc. (US) 2026-04-22 EP disclosed
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF ADAXION THERAPEUTICS, INC. 2025-02-27 US disclosed
WO-2024259007-A2 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF OSPREY BIOPHARMACEUTICALS, INC. (US) 2024-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250064941-A1 SIGLEC LIGANDS, CONJUGATES, AND METHODS OF USE THEREOF SIGLEC7, SIGLEC9, CD2BP2 SMN1; SMN2 2857/4885SENP1 1471/4885KMT2A 2898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.